GSI-136 is an investigational drug.
There have been 13 clinical trials for GSI-136.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2002.
The most common disease conditions in clinical trials are Alzheimer Disease, Osteosarcoma, and Neoplasms. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, National Cancer Institute (NCI), and Baylor College of Medicine.